Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
220M shares
52-week range
$6.23 – $16.44
38% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
43.9
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
www.ocutx.comNo one on the platform currently holds OCUL.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,147,982 | $9.7M |
No one on the platform has traded OCUL yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -18.7% | 24.4% | ||||
| Profit Margin % | -513.2% | -221.6% | -1261.0% | |||
| Free Cash Flow Margin % | -418.5% | -207.8% | -1076.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $53M | -3.5% | $-1.50 | $-1.57–$-1.44 | — | 7 |
| 2027 | $101M | +90.4% | $-1.47 | $-1.74–$-0.99 | — | 7 |
| 2028 | $287M | +185.1% | $-1.02 | $-1.84–$-0.45 | — | 6 |
| 2029 | $636M | +121.8% | $0.02 | $0.01–$0.03 | 508.0× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $-0.40 | $-0.35 | +11.5% |
| 2026-05-05 | $-0.32 | $-0.41 | -28.1% |
| 2026-02-05 | $-0.33 | $-0.29 | +12.1% |
| 2025-11-04 | $-0.39 | $-0.37 | +5.1% |
| 2025-08-05 | $-0.35 | $-0.39 | -11.4% |
| 2025-05-05 | $-0.29 | $-0.37 | -27.6% |
| 2025-03-03 | $-0.24 | $-0.29 | -20.8% |
| 2024-11-14 | $-0.23 |
| $-0.26 |
| -13.0% |
| $2.2B |
| — |
| IBRXImmunityBio, Inc. | $8.18 | +0.46% | $8.6B | — |
| LQDALiquidia Corporation | $66.31 | +0.89% | $5.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
$OCUL $OCUL BofA important regulatory step forward in securing the first approval for Axpaxli. remain bullish on the large potential commercial opportunity for Axpaxli in wAMD and other retinal disease given its differentiated long-acting profile. OCUL remains a top pick with a Buy $27 PT
View on StockTwits ↗
$EYPT and $OCUL will both have a hard time going against current antivegf treatments. TKI’s work but not floating around the vitreous for 6-9 months. Right drug, wrong delivery. Eypt happened, ocul is next.
View on StockTwits ↗
$XBI $OCUL LMAO!! always someone elses fault when the stock drops. my goodness the coping mechanisms are out of control.
View on StockTwits ↗
$OCUL anytime! Meetings are going well…really well. Market environment is rough for a high beta stock though. Have a great evening!
View on StockTwits ↗
@ShortSuckieTuckie @Appulen EYPT presented at Morgan Stanley this morning and were waxing poetic about "bad luck" with the Control Arm of their failed study being the blame for all things and they mentioned raising more money and using synthetic structures or something to that effect to get there. The Market (on a day most of the $XBI was getting hit, including $OCUL ), no likey.
View on StockTwits ↗$OCUL i am having a great week so far, thanks bud. more pre meetings and conferences, please! they are going SO well!
View on StockTwits ↗$OCUL please, more conferences. the mouths open, the stock drops! god, what an easy short this is. sorry to the longs, lmao!
View on StockTwits ↗
$OCUL EYPT stock got destroyed today for unknown reasons, perhaps as a result of Ocul successful FDA announcement today. Ocul is still very much correlated to EYPT stock, they are both entertwined due to similar TKI drug development. Today's Ocul price drop has very low volume behind it and could be the algorithms trading based on the said correlation between both companies. Eventually Ocul will detach from EYPT orbit and create it's own price trajectory. If you compare both Ocul and Eypt 3 year charts simultaneously, they basically dance and hug eachother. We are in the midst of the point of separation.
View on StockTwits ↗
@Jdliberty You do not understand the SOL-1 results or the SOL-R design. You are also not going to see SOL-R results for a long time given the modified prodigal. $OCUL has much better studies and data than $EYPT. They have 2/3 of patients going a full year on one injection. The stat significance is awesome with values like p<.0001. If you listen to $EYPT PR without taking a close look at the numbers, you get it really wrong.
View on StockTwits ↗$OCUL $XBI whats so exciting about this? sensationalism at its finest. unreal.
View on StockTwits ↗@ArmyGreen4Runner I suggest you compare this to the $OCUL presentation this morning.
View on StockTwits ↗$OCUL lololol okay. just like the september calls know what they were doing right? thanks for the free money.
View on StockTwits ↗
$OCUL PDaddy glad to remind everyone at the conference that Eyepoint failed....and he gets no joy from this =)
View on StockTwits ↗$OCUL i would get your shorts in before the conference- you know when they open their mouth, the stock drops. god, i can't believe the poor sap with all those calls on the line that are going to expire worthless. i believe alanis morrissette once said "you live, you learn"! LMAO
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.